Subscribe and receive the latest insights on the health and nutrition industry.
Join 37,000+ members. Yes, it's completely free.
October 29, 2013
HOBOKEN, N.J. New clinical research published in Otorinolaringologia found natural supplement Pycnogenol® in combination with vitamin C and zinc shortened the duration and lessened the symptoms of the common cold.
The common cold affects the average adult two to five times each year, which can have a major effect on work and home life," said Dr. Fred Pescatore, expert and practitioner in health and nutritional medicine. This research shows that Pycnogenol®, taken in conjunction with vitamin C and zinc, can help to shorten the duration of a cold and reduce some of its main symptoms, which makes this natural supplement valuable for the recovery process and for controlling cold-related costs and missed work days."
The new study evaluated the effect of Pycnogenol® (from Horphag Research) on the signs and symptoms of an established cold in four variations: Pycnogenol® alone; Pycnogenol® plus vitamin C; Pycnogenol® plus gluconate zinc and a trio combining all three. These groups were compared to each other and to a control group only using over-the-counter (OTC) cough and cold products. The trio (100mg Pycnogenol®, 200mg vitamin C and 30mg gluconate zinc per day) showed the most success in significantly shortening the duration of symptoms to four days, compared to the average of seven days. The other three variations also out-performed the control group in daily regression of the pillar cold symptoms including runny nose, nasal obstruction, sore throat, sneezing, high temperature, cough and general discomfort.
In this study, we found that taking Pycnogenol® with vitamin C and zinc for at least five days in episodes of the common cold can shorten the course of a cold and decrease symptoms," said Gianni Belcaro, a lead researcher of the study. The results of the study demonstrate the effects of a supplement plan using Pycnogenol® alone or in association with other supplements to reduce the symptoms and severity of the common cold."
The study was conducted at the Chieti-Pescara University in Pescara, Italy, and focused on two phases to evaluate the effects of the four supplement variations. The first phase followed 73 healthy volunteers with no history of serious illness. At the first sign of a cold, 40 subjects in this group supplemented with 50 mg of Pycnogenol® twice daily while 33 patients only used over-the-counter (OTC) treatment. The effect of Pycnogenol® alone was statistically significant; key results within this group included the duration of the cold being significantly decreased in comparison with controls which resulted in a decrease of lost working days and a decrease of the need to use OTC treatment. The second phase followed 196 patients with colds, which were divided into three groups and given the three separate variations of supplementation for five days or more. Both phases of the study evaluated subjects between the ages of 25 to 70 and conducted a follow-up examination after three days.
The Pycnogenol® and vitamin C combination performed better, and had a synergistic effect, to aid in faster recovery from the common cold. Immune system cells, called leukocytes, require a significant amount of vitamin C to naturally recover from the common cold. Research shows that Pycnogenol® metabolites were found in leukocytes through the GLUT1 transporter in a study earlier this year. Therefore, the Pycnogenol® and vitamin C interaction demonstrated improved natural immunity due to the synergistic antioxidant effect of the combination.
Pycnogenol® alone and also in combination with the other ingredients was found to control excess inflammation and swelling in the nasal mucus membrane, which is common in patients with colds.
You May Also Like
9 of 10 Amazon galantamine memory supplements failed to meet label claimFeb 23, 2024
ABC reports herbal sales fell 1.9% in 2022Feb 22, 2024
Here's why creatine sales are surging this past yearFeb 21, 2024
DSHEA's 25th anniversary: Industry vets, critics respondFeb 21, 2024